Antidepressants Produce Similar Remission Rates, NIMH Study Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
Wellbutrin SR, Zoloft and Effexor XR all provide “reasonable second step” for treatment-resistant depression, STAR*D trial suggests.
You may also be interested in...
Wyeth Emphasizes Effexor XR’s Second-Line Bona Fides
The company responds to a study suggesting its venlafaxine antidepressant had not previously shown second-line efficacy.
Nexavar “Very Competitive” With Pfizer’s Sutent, Bayer Says
Bayer’s kidney cancer drug brought in $25.2 mil. (€20 mil.) in the first quarter following its approval late last year.